MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. - Stroh J; Seckinger A; Heider M; Rudelius M; Eichner R; Schick M; Slawska J; Emde-Rajaratnam M; Salwender H; Bertsch U; Goldschmidt H; Weisel K; et al. (Blood advances, 2022)